Melanoma-associated antigen 3 peptide–Major Histocompatibility Complex class I complex (MAGE-A3–MHC I complex)

The MAGE-A3 peptide–MHC class I complex is a specific molecular target formed when the intracellular cancer-testis antigen MAGE-A3 is processed into peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, typically HLA-A*01 or HLA-A*02. MAGE-A3 is highly expressed in various malignancies, including melanoma and lung cancer, but is restricted to immune-privileged germ cells in healthy tissues, making its surface-presented peptide an attractive target for T-cell based therapies. Therapeutic strategies targeting this complex include T-cell receptor (TCR) engineered T-cells and cancer vaccines designed to stimulate a cytotoxic T-lymphocyte response against tumor cells. However, clinical development has faced significant challenges due to lethal off-target toxicities; for instance, early TCR therapies showed cross-reactivity with the muscle protein Titin and other MAGE family members in the central nervous system. Despite these risks, the complex remains a high-priority target for precision immunotherapy due to its high tumor specificity and the potential for deep clinical responses in MAGE-A3-positive patients.

Other names

MAGE-A3/HLA complexMAGE-A3/MHC complexMAGE3 peptide-MHCpMHC MAGE-A3HLA-A*01:01/MAGE-A3 complex

T-cell receptor (TCR) binding, T-cell mediated cytotoxicity, Induction of adaptive immune response